Onc Club | Videos

Dr Braun on Fundamental Immune Defects in Chromophobe RCC

July 31st 2025

David A. Braun, MD, PhD, discusses immune defects in patients with chromophobe RCC vs clear cell RCC.

Dr Kuerer on the Safety, Feasibility of Omitting Surgery in Select Patients With HER2+, Triple-Negative Breast Cancer

July 31st 2025

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses the feasibility of eliminating surgery in select patients with a pCR after neoadjuvant therapy for breast cancer.

Dr Patel on the p53 IHC Positivity as Potential Surrogate for Multi-Hit TP53 Mutations in MDS and AML

July 25th 2025

Shyam A. Patel, MD, PhD, discusses the threshold of p53 IHC positivity best correlating with multi-hit TP53 mutational status in MDS and AML.

Dr Emadi on Initial Responses With Venetoclax Plus PegC in R/R AML

January 6th 2025

Ashkan Emadi, MD, PhD, discusses responses achieved with venetoclax plus PegC in patients with venetoclax-pretreated, relapsed/refractory AML.

Dr Watson on the Use of Oncogene Analysis to Determine Clinically Relevant HER2, KRAS and MET Copy-Number Gain in NSCLC

December 20th 2024

Alec Watson, MD, discusses clinically relevant thresholds for HER2, KRAS, and MET gene copy number gain set by oncogene overlap analysis in NSCLC.

Dr Kelly on ctDNA Dynamics Following Neoadjuvant Immunotherapy in GEJ Cancer

May 20th 2024

Ronan J. Kelly, MD, MBA, FASCO, discusses the predictive value of ctDNA following neoadjuvant immunotherapy in resectable gastroesophageal cancer.

Dr Feigin on the Effect of Benzodiazepines on Survival Outcomes in Pancreatic Cancer

October 7th 2023

Michael Feigin, PhD, discusses data from a retrospective study investigating the association between benzodiazepines and survival outcomes in patients with pancreatic cancer.

Dr. Ehrhardt on Factors Associated with Late Mortality in Survivors of Childhood Cancer

February 24th 2023

Matthew J. Ehrhardt, MD, MS, discusses the link between modifiable chronic health conditions and social determinants of health with late mortality for survivors of childhood cancer.

Dr. Kishan on the MIRAGE Trial of MRI-Guided SBRT in Prostate Cancer

January 30th 2023

Amar U. Kishan, MD, discusses interim results from the phase 3 MIRAGE trial of magnetic resonance imaging–guided stereotactic body radiotherapy in prostate cancer.

Dr. Jakubowiak on Initial Efficacy Data From the ATLAS Trial in Multiple Myeloma

January 30th 2023

Andrzej Jakubowiak, MD, PhD, discusses initial efficacy results from the phase 3 ATLAS trial in multiple myeloma.

Dr. Pecora on Key Efficacy Findings from the DREAMSEQ Trial in BRAF-Mutated Melanoma

November 3rd 2022

Andrew L. Pecora, MD, discusses the key efficacy findings from the phase 3 DREAMSEQ trial in BRAF-mutated melanoma.

Dr. Saba on the Investigation of Pembrolizumab Plus Cabozantinib in HNSCC

November 2nd 2022

Nabil Saba, MD, FACP, discusses the evaluation of pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma.

Dr. Khan on Racial Disparities with Patient Surgical Outcomes in GI Tract Cancer

April 28th 2022

Sajid A Khan MD, FACS, FSSO, discusses racial disparities with patient surgical outcomes in gastrointestinal tract cancer.

Dr. Taylor on Findings from a Genomic Analysis on BTK Inhibitors in CLL

April 27th 2022

Justin W. Taylor, MD, discusses findings from a genomic analysis on BTK inhibitors in chronic lymphocytic leukemia.

Dr. Scott on the Incorporation of GARD-Based Radiotherapy Dosing in Oncology

August 30th 2021

Jacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Dr. Halmos on the Efficacy of COVID-19 Vaccines in Patients With Cancer

June 25th 2021

Balazs Halmos, MD, discusses the efficacy of the COVID-19 vaccines in patients with cancer.

Dr. Landgren on the Clinical Impact of KRd-D in Multiple Myeloma

May 13th 2021

Ola Landgren, MD, PhD, discusses the clinical impact of the 4-drug combination of carfilzomib, lenalidomide, dexamethasone, and daratumumab in patients with multiple myeloma.

Dr. Maura on the Significance of Studying Myeloma Genomic Defining Events

April 26th 2021

Francesco Maura, MD, discusses the significance of studying genomic defining events in patients with multiple myeloma.

Dr. Landgren on the Rationale For Examining Whole Genome Sequencing in Smoldering Myeloma

April 26th 2021

Ola Landgren, MD, PhD, discusses the rationale behind examining whole-genome sequencing in smoldering myeloma.

Dr. Motzer on the Efficacy of Cabozantinib in RCC

March 18th 2021

Robert J. Motzer, MD, discusses the efficacy of cabozantinib in patients with renal cell carcinoma.